OncoMatch/Clinical Trials/NCT06339060
An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).
Is NCT06339060 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Experimental: Arm 1 Organ preservation and Active Comparator: Arm 2 Surgery for esophageal cancer.
Treatment: Experimental: Arm 1 Organ preservation · Active Comparator: Arm 2 Surgery — Patients with locally advanced esophageal squamous cell carcinoma will randomly assigned to receive neoadjuvant chemo-radiotherapy combined with immunotherapy post organ preservation strategy (experimental group) or neoadjuvant chemo-radiotherapy followed by surgery (control group). The 3-year overall survival rate is the primary outcome.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT2-T4A, N0-N+
cT2-T4a,N0-N+,M0 resectable esophageal squamous cell carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Cannot have received: radiotherapy
Cannot have received: targeted therapy
Cannot have received: immunotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify